Outcomes of Intralesional Interferon Alpha-2B for the Treatment of Peyronie's Disease
Trost LW, Ates E, Powers M, Gur S, Sikka S, Hellstrom WJ. J Urol. 2013 May 17. pii: S0022-5347(13)04358-9. doi: 10.1016/j.juro.2013.05.022. [Epub ahead of print]


Tulane University, New Orleans, LA; Mayo Clinic, Rochester, MN.



To evaluate the efficacy of intralesional interferon alpha-2b (IFN) in Peyronie's Disease (PD), review the impact of timing of therapy from disease onset, and identify variables predictive of response.


A retrospective chart review was performed of patients undergoing intralesional IFN from 2001-2012. Demographic information, disease characteristics, pre- and post-treatment penile duplex ultrasound (U/S) findings, and objective measures were analyzed. Response was defined as ≥20% improvement in curvature. Statistical analyses were performed to identify significant changes in variables and identify predictive factors.


A combined 127 patients with a mean age of 55 years (range 25-76) and mean pre-treatment curvature of 42.4 degrees (SD 18.6) underwent a median of 12, biweekly IFN injections (range 6-24). Median duration of PD was 2.0 years (range 0.5-23). Fifty-four percent of patients responded to therapy, with an overall mean improvement of 9.0 degrees (p<0.001). Patients with curvatures <30 degrees were most likely to experience a ≥20% improvement with IFN (86% response, p<0.001); however, similar overall curvature improvements were noted among all pre-treatment curvatures. No statistically significant improvements were noted with penile vascular status or U/S parameters. Duration of PD did not impact change in curvature. Age, pretreatment curvature, vascular status, penile U/S findings, location of curvature, and International Index of Erectile Function score did not predict response to therapy.


Intralesional therapy with IFN results in significantly improved curvature without impact on penile vascular parameters. Absolute improvement in curvature is independent of pre-treatment curvature and duration of PD.